TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03378713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP 1: Long testosterone
Description: Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP 2: Short testosterone
Description: Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP 3: Control
Description: The COS starts directly on the second day of the cycle without prior medication.
Study: NCT02140814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide
Study: NCT04094571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) Control Protocol
Description: To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) Angle Protocol
Description: To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
Study: NCT04066972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
Study: NCT03284736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resorbable membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery without membrane
Description: after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
Study: NCT02385422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study: NCT01381432

Intervention type: DRUG
Intervention: Azathioprine
Description: At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
Study: NCT01779973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Observed Dosing
Study: NCT03600662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TriRec
Description: Trileaflet Reconstruction of the Aortic Valve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Description: Biological Prosthesis, Device: St. Jude Medical Trifecta GT
Study: NCT02385422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study: NCT01756131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo
Study: NCT03857490

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lower leg heat therapy
Description: Home-based 8 weeks of lower leg repeated heating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg heat therapy
Description: Home-based 8 weeks of lower leg repeated heating.
Study: NCT03698435

Intervention type: DRUG
Intervention: Ganciclovir
Description: Intravenous ganciclovir + TDM

Intervention type: DRUG
Intervention: Ganciclovir
Description: Intravenous ganciclovir + TDM

Intervention type: DRUG
Intervention: Valganciclovir
Description: Oral valganciclovir + TDM

Intervention type: DRUG
Intervention: Valganciclovir
Description: Oral valganciclovir + TDM
Study: NCT02459795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Perrigo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT01285115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KyungBangn-Gamisoyosan-x-gwarip
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KyungBangn Gamisoyosan
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study: NCT03794336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT01389752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study: NCT03794336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Pharmaceutical form: tablet~Route of administration: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT01389752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Administered orally
Study: NCT03794336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT01709435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03794336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Pharmaceutical form: tablet~Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study: NCT00373113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: 37.5 mg daily, continuous dosing
Study: NCT01709435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03720431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001 and pembrolizumab combination
Description: * Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)
Study: NCT01250600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Daily home exercise for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Daily home exercise for 3 months
Study: NCT00825500

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato placebo (0 mg)
Study: NCT05466617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health for Physical Activity Behavior Change
Description: All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
Study: NCT00825500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Loxapine 1.25 mg
Description: Inhaled Staccato Loxapine 1.25 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 2.5 mg
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Study: NCT04457804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual ACT Workshop for Emotional Eating
Description: This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness.
Study: NCT01485757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
Study: NCT03285737

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: Supplement provided twice daily in 30g doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen
Description: Supplement provided twice daily in 30g doses
Study: NCT03841630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03496246

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: seum alanine aminotransferase
Description: for assessment of liver function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: seum alanine aminotransferase
Description: for assessment of liver function
Study: NCT03278353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
Study: NCT03496246

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: seum alanine aminotransferase
Description: for assessment of liver function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum potassium level
Description: indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
Study: NCT02807584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELECT
Study: NCT03496246

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum potassium level
Description: indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum potassium level
Description: indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum phosphurus level
Description: measurement of phosphurus level as it is closely related to vitamin d with its effects on its level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum phosphurus level
Description: measurement of phosphurus level as it is closely related to vitamin d with its effects on its level

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum phosphurus level
Description: measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
Study: NCT01338454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transamin
Description: TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
Study: NCT01652469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day p.o. continuously with 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion every 21 days.
Study: NCT00337675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15
Study: NCT01830504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.
Study: NCT02742285

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether + lumefantrine
Description: A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
Study: NCT01056627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21
Study: NCT01056627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21
Study: NCT04319978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
Study: NCT03535727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15